New frameworks to assess value of cancer care: Strengths and limitations

Oncologist

Volumn 21, Issue 6, 2016, Pages 654-658

  Schnipper, Lowell E ^a   Bastian, Alex ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b GfK Market Access   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER CENTER; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONCEPTUAL FRAMEWORK; DECISION MAKING; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SURVEY; HEALTH CARE SYSTEM; HUMAN; NOTE; ONCOLOGY WARD; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; COST; DRUG COST; ECONOMICS; NEOPLASM; UNITED STATES;

COSTS AND COST ANALYSIS; DRUG COSTS; HUMANS; NEOPLASMS; UNITED STATES;

EID: 84975226256     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0177     Document Type: Note

References (18)

1. Mariotto AB, Yabroff KR, Shao Y et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103:117-128.
2. USA Today, Kaiser Family Foundation, Harvard School of Public Health: National survey of households affected by cancer. Available at http://www.kff.org/kaiserpolls/7590.cfm. Accessed May 18, 2016.
3. Himmelstein DU, Thorne D, Warren E, Woolhandler S. Medical bankruptcy in the United States, 2007: Results of a national study. Am J Med 2009;122:741-746.
4. Bernard DSM, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol 2011;29:2821-2826.
5. Henry J. Kaiser Family Foundation. 2015 Employer health benefits survey. Available at http://kff.org/report-section/ehbs-2015-summary-of-findings/. Accessed May 18, 2016.
6. Shankaran V, Jolly S, Blough D et al. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: A population-based exploratory analysis. J ClinOncol 2012;30:1608-1614.
7. Bullock AJ, Hofstatter EW, Yushak ML et al. Understanding patients’ attitudes toward communication about the cost of cancer care. J Oncol Pract 2012;8: e50-e58.
8. Wong YN, Hamilton O, Egleston B et al. Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices. The Oncologist 2010;15: 566-576.
9. Snyder LS. Review of the American College of Physicians Ethics Manual: Sixth edition. Ann Intern Med 2012;156:73-104.
10. Schnipper LE, Davidson NE, Wollins DS et al. American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options. J Clin Oncol 2015;33:2563-2577.
11. Cherny NI, Sullivan R, Dafni U et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015;26: 1547-1573.
12. National Comprehensive Cancer Network. Available at http://www.nccn.org/evidenceblocks/pdf. Accessed May 20, 2016.
13. Institute for Clinical and Economic Review. Methods. The ICER approach. Available at http://icer-review.org/methodology/icers-methods/. Accessed May 20, 2016.
14. De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE-5-a population-based study. Lancet Oncol 2014;15:23-34.
15. Ellis LM, Bernstein DS, Voest EE et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 2014;32:1277-1280.
16. Memorial Sloan Kettering Cancer Center. Drug Abacus. Available at http://www.drugabacus.org/drug-abacus-tool. Accessed May 20, 2016.
17. Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-2595.
18. Perez EA, Romond EH, Suman VJ et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTGN9831. J ClinOncol 2014;32: 3744-3752.